Anticancer therapies that employ immune checkpoint inhibitors are implicated in idiopathic DCM pathogenesis, as these agents block tumor necrosis factor (TNF)-mediated inhibition of cytotoxic T cells (79). Here, TNF is linked to familial dilated cardiomyopathy.